Eli Lilly and (NYSE:LLY) Price Target Raised to $375.00 at Berenberg Bank

Eli Lilly and (NYSE:LLYGet Rating) had its price target hoisted by Berenberg Bank from $345.00 to $375.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s target price would suggest a potential upside of 3.67% from the stock’s current price.

A number of other brokerages also recently issued reports on LLY. The Goldman Sachs Group increased their price target on Eli Lilly and from $281.00 to $313.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 8th. Credit Suisse Group assumed coverage on Eli Lilly and in a research report on Thursday, November 17th. They set an “outperform” rating and a $395.00 price target on the stock. UBS Group upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and raised their target price for the company from $335.00 to $363.00 in a research report on Thursday, September 22nd. Truist Financial raised their target price on Eli Lilly and from $400.00 to $421.00 in a research report on Tuesday, November 15th. Finally, Citigroup raised their target price on Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and presently has a consensus rating of “Moderate Buy” and an average price target of $359.78.

Eli Lilly and Stock Performance

Shares of LLY stock opened at $361.72 on Tuesday. The company has a market capitalization of $343.70 billion, a P/E ratio of 54.33, a P/E/G ratio of 2.27 and a beta of 0.36. The business’s 50 day moving average is $337.81 and its two-hundred day moving average is $320.94. The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 1.39. Eli Lilly and has a 12-month low of $231.87 and a 12-month high of $369.80.

Insiders Place Their Bets

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 63,585 shares of the firm’s stock in a transaction on Monday, November 7th. The stock was sold at an average price of $363.94, for a total transaction of $23,141,124.90. Following the completion of the sale, the insider now owns 103,158,810 shares of the company’s stock, valued at $37,543,617,311.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 63,585 shares of the firm’s stock in a transaction on Monday, November 7th. The stock was sold at an average price of $363.94, for a total transaction of $23,141,124.90. Following the completion of the sale, the insider now owns 103,158,810 shares of the company’s stock, valued at $37,543,617,311.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction on Monday, October 10th. The shares were sold at an average price of $326.23, for a total value of $214,006.88. Following the completion of the sale, the executive vice president now directly owns 6,950 shares of the company’s stock, valued at $2,267,298.50. The disclosure for this sale can be found here. Insiders sold a total of 571,297 shares of company stock valued at $193,929,777 over the last quarter. 0.12% of the stock is owned by insiders.

Institutional Investors Weigh In On Eli Lilly and

Institutional investors have recently modified their holdings of the company. Minot Wealth Management LLC grew its stake in shares of Eli Lilly and by 344.2% in the second quarter. Minot Wealth Management LLC now owns 12,379 shares of the company’s stock valued at $4,014,000 after buying an additional 9,592 shares in the last quarter. Csenge Advisory Group boosted its holdings in Eli Lilly and by 9.0% in the second quarter. Csenge Advisory Group now owns 4,009 shares of the company’s stock valued at $1,300,000 after purchasing an additional 332 shares during the period. Guardian Wealth Advisors LLC NC purchased a new position in Eli Lilly and in the first quarter valued at $260,000. Connors Investor Services Inc. boosted its holdings in Eli Lilly and by 18.0% in the first quarter. Connors Investor Services Inc. now owns 51,553 shares of the company’s stock valued at $14,763,000 after purchasing an additional 7,850 shares during the period. Finally, Navellier & Associates Inc. purchased a new position in Eli Lilly and in the second quarter valued at $5,828,000. 82.45% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

The Fly logo

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.